文献类型：期刊文献

中文题名：Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor

作者：Xiao-Ke Wang[1];Xin Yang[1];Tong-Han Yao[1];Peng-Xian Tao[2];Guan-Jun Jia[3];De-Xian Sun[4];Lin Yi[3];Yuan-Hui Gu[2]

第一作者：Xiao-Ke Wang

机构：[1]The First School of Clinical Medical,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China;[2]Department of General Surgery,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China;[3]School of Traditional Chinese and Western Medicine,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China;[4]Graduate School,Qinghai University,Xining 810016,Qinghai Province,China

第一机构：甘肃中医药大学

年份：2024

卷号：16

期号：7

起止页码：2915

中文期刊名：World Journal of Gastrointestinal Oncology

外文期刊名：世界胃肠肿瘤学杂志(英文)

基金：Supported by the National Natural Science Foundation of China,No.82160842;Clinical Research Project of Research Fund of Gansu Provincial Hospital,No.23GSSYD-17.

语种：英文

中文关键词：Gastrointestinal stromal tumor;M2 macrophage;Inflammatory response;Programmed death receptor-1;Programmed death ligand-1;Imatinib;Immunotherapy;Targeted therapy

摘要：Gastrointestinal stromal tumors(GIST)are the most common mesenchymalderived tumors of the GI tract.They can occur throughout the GI tract,and the survival time of some patients can be improved by first-line targeted therapy with imatinib.However,there are some limitations with imatinib treatment.Immunotherapy for GIST has attracted much attention in recent years,and as one of the most abundant cells in the GIST microenvironment,M2 macrophages play an important role in disease progression.They have unique anti-inflammatory and pro-tumorigenic effects and are one target for immunotherapy.This review summarizes the connection between different factors and the programmed death receptor-1/programmed death ligand-1 pathway and M2 macrophages to reactivate or enhance anti-tumor immunity and improve imatinib efficacy,and to provide new ideas for GIST immunotherapy.